RxDoctor Payments Data

Willeen Roy

Family · Chattanooga, TNNPI 1760014476

Payments from drug & device makers

$867in general payments, 2019–2025

Across 27 payments — averaging $32.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$410
  • AbbVie$139
  • AstraZeneca$122
  • Smith+Nephew$122
  • Bayer$22
  • Kowa Pharmaceuticals America, Inc.$21
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$867100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$867 in reported general payments places this provider in the 60th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$66,492
Medicare patients
149
Services billed
668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$116,431
OzempicSemaglutide29$43,452
MounjaroTirzepatide41$43,180
LinzessLinaclotide41$29,787
JanuviaSitagliptin Phosphate38$29,640
XareltoRivaroxaban18$20,469
VraylarCariprazine Hcl11$18,433
MyrbetriqMirabegron35$18,135
FarxigaDapagliflozin Propanediol26$15,420
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$12,236
Breo ElliptaFluticasone/Vilanterol25$9,596
EntrestoSacubitril/Valsartan12$9,001
JardianceEmpagliflozin13$7,569
TradjentaLinagliptin12$5,105
Potassium Chloride179$2,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Vraylar$139$48,22052 claims
Novo NordiskOzempic$410$43,45229 claims
AstraZenecaFarxiga$122$15,42026 claims
Boehringer IngelheimJardiance, Tradjenta$17$12,67425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,706 family providers in Tennessee.

Other family in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →